Revision as of 20:33, 19 April 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{chembox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation (← Previous edit | Revision as of 16:28, 12 September 2011 edit undoPotatoBot (talk | contribs)Bots51,239 editsm Stub sorting and placement of stub template(s): antiinfective-drug-stub. See approval. Report errors and suggestions at User talk:PotatoBot.Next edit → | ||
Line 42: | Line 42: | ||
{{ |
{{antiinfective-drug-stub}} |
Revision as of 16:28, 12 September 2011
This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (April 2011) |
Names | |
---|---|
IUPAC name 3--6-(4-pentylphenyl)furopyrimidin-2-one | |
Other names Cf1743 | |
Identifiers | |
3D model (JSmol) | |
PubChem CID | |
CompTox Dashboard (EPA) | |
SMILES
| |
Properties | |
Chemical formula | C22H26N2O5 |
Molar mass | 398.459 g·mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). Y verify (what is ?) Infobox references |
FV-100, also known as Cf1743, is an orally available nucleoside analogue drug with antiviral activity. It may be effective against shingles.
It was discovered in 1999.
Clinical trials
It is in a phase II trial against valaciclovir in patients with herpes zoster.
References
- Inhibitex Completes Phase I Clinical Trials For FV-100 And Selects Lead HCV Compounds For Advanced Preclinical Studies, 2009
- McGuigan, Christopher; Balzarini, Jan (2009). "FV100 as a new approach for the possible treatment of varicella-zoster virus infection". Journal of Antimicrobial Chemotherapy. 64 (4): 671–673. doi:10.1093/jac/dkp294. PMID 19679595.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - , 2010 http://www.dailymail.co.uk/health/article-515969/Thousands-spared-pain-shingles.html,
And at Cardiff University, Chris McGuigan, professor of medicinal chemistry, has developed a new drug for shingles, FV-100, which is doing well in phase I trials. FV 100 looks like it will be very potent (more than 10,000 times as strong as aciclovir), safe and could prevent long-term pain, too. It could be on the market by 2010.
{{citation}}
: Missing or empty|title=
(help) - Step forward for shingles drug - FV100 Shows structure of FV100
- A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster
This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it. |